Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System
NCT00698425
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
105
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
OTHER:
EyeGate II® Drug Delivery System
DRUG:
Citrate buffer
Sponsor
Eyegate Pharmaceuticals, Inc.